Rituxan (rituximab) - Roche
mycophenolate mofetil - Generic mfg.
Efficacy and safety of mycophenolate mofetil in preventing relapse of IgG4-related disease with re-elevation of serum IgG4 level during maintenance therapy: a protocol for a multicentre, randomised, double-blind, placebo-controlled study in China. (PubMed, BMJ Open) - Sep 13, 2026 - P=N/A | "Glucocorticoids and/or immunosuppressants as well as rituximab are both first-line treatments in remission induction therapy. Findings will be disseminated through peer-reviewed journals and conference presentations. NCT05974683." 
Clinical protocol • Journal • Inflammation • Rheumatology
http://www.ncbi.nlm.nih.gov/pubmed/42731845
 
Changyan Liu; Jialei Zhang; Jiaxin Zhou; Lingli Dong; Linyi Peng; Mengtao Li; Min Fu; Wen Zhang; Xia Zhang; Xiaodan Kong; Yanying Liu; Yu Chen; Yunyun Fei; Yuxue Nie
 
Sep 13, 2026
 
Prev Next